Dulaglutide vs Exenatide: What the Research Compares

What this page compares

Dulaglutide and exenatide are prescription medicines, both approved for use in type 2 diabetes and both belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class described in a state-of-the-art review of the class (PMID 33068776). This page sets out what the published literature reports when the two are examined alongside each other: the shape of the evidence base, the class pharmacology, the regulatory position and the adverse events described in trials and reviews. It does not rank the two medicines, does not describe one as preferable, and contains no dosing directions. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including dulaglutide and exenatide.

Head-to-head randomized trials in this citation set

The verified papers summarised on this page do not include a direct head-to-head randomized trial in which dulaglutide was given in one arm and exenatide in another with a shared primary endpoint. Stated plainly: no such trial is cited here, and so no head-to-head effect estimate, no between-drug difference and no trial-named result is reported on this page. What the literature summarised below does contain is a different kind of comparison, in which researchers pooled or networked separate randomized trials of individual GLP-1 receptor agonists and reported class-level and agent-level estimates.

Network meta-analysis is the method used when direct comparisons are sparse. A systematic review and network meta-analysis of glucose-lowering drugs in type 2 diabetes compared drug classes added to background therapy and reported outcomes across glycemic control, mortality and adverse events, with GLP-1 receptor agonists among the classes assessed (PMID 32598218). Estimates produced this way rest on indirect comparison through shared comparators rather than on randomization between dulaglutide and exenatide, which is why the authors of class reviews repeatedly frame such results as hypothesis-generating rather than definitive (PMID 33068776).

Side by side: the separate evidence bases

Class and mechanism

Both medicines act at the GLP-1 receptor. The class review described how GLP-1 receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying and reduce appetite, and it grouped the marketed agents by structural origin and duration of action (PMID 33068776). Exenatide is based on exendin-4, a peptide structurally distinct from human GLP-1, while dulaglutide is a human GLP-1 analogue linked to an immunoglobulin fragment that extends its circulating half-life; the same review discussed how these structural strategies produce agents with differing pharmacokinetic profiles within one receptor class (PMID 33068776).

Formulation differences matter for how trials were designed. Research on GLP-1 receptor agonists has examined subcutaneous and oral delivery of the same molecule, and one analysis of semaglutide formulations reported that route of administration influenced exposure and measured glycemic response (PMID 34248838). That finding concerns semaglutide specifically, not dulaglutide or exenatide, and is noted here only to illustrate why formulation is treated as a variable in class research.

Glycemic and weight outcomes reported across the class

Researchers conducting a network meta-analysis of glucose-lowering drugs reported comparative estimates across classes in adults with type 2 diabetes, with GLP-1 receptor agonists assessed alongside other treatment options for glycemic and clinical outcomes (PMID 32598218). A separate review of weight effects reported that agents in the GLP-1 receptor agonist class were associated with weight reduction in patients with type 2 diabetes, in contrast with several other glucose-lowering drug categories examined in the same review (PMID 34302978).

Pediatric evidence has also been synthesised. A systematic review and network meta-analysis of GLP-1 receptor agonists in children and adolescents with obesity or overweight compared agents in the class and reported differences in body mass index outcomes and in reported adverse events between the studied drugs (PMID 39065679). That analysis addressed a population and an indication distinct from adult type 2 diabetes, and its results do not transfer to the adult comparison.

Cardiovascular outcome literature

Both agents have been studied in dedicated cardiovascular outcome trials, and those trials were pooled rather than compared directly. A systematic review and meta-analysis of cardiovascular outcome trials of GLP-1 receptor agonists reported a reduction in major adverse cardiovascular events of approximately 12 percent compared with placebo, together with reductions in all-cause mortality and in composite kidney outcomes, and reported no increase in severe hypoglycemia, pancreatitis or pancreatic cancer across the pooled trials (PMID 31422062).

A larger and more recent systematic review and meta-analysis covering 99,599 patients again examined cardiovascular effects and tolerability of GLP-1 receptor agonists as a class and reported both the cardiovascular findings and the tolerability signals that accompanied them (PMID 40892610). Pooled analyses of this kind describe the class average. They do not establish that any one agent in the class, dulaglutide or exenatide included, produced the pooled estimate, and the authors of the class review emphasised that individual trials differed in population, background therapy and follow-up duration (PMID 33068776).

Agent-specific cardiovascular analyses exist for other members of the class as well. One analysis examined cardiovascular safety and benefit findings from two semaglutide outcome programmes and reported results for that molecule (PMID 33854484), which again illustrates that evidence in this class is generated agent by agent rather than through direct comparison between agents.

Adverse Events: What Studies Report

Gastrointestinal effects dominate the reported adverse event profile for the class. The state-of-the-art class review reported nausea, vomiting and diarrhoea as the most frequent adverse events associated with GLP-1 receptor agonists, generally described as dose-related and more common early in treatment (PMID 33068776). The 2025 meta-analysis of 99,599 patients assessed tolerability alongside cardiovascular endpoints and reported adverse event and discontinuation findings for the class (PMID 40892610).

Pooled cardiovascular outcome data addressed several safety questions directly. The study pooling those trials reported no increase in severe hypoglycemia, pancreatitis or pancreatic cancer with GLP-1 receptor agonists compared with placebo (PMID 31422062). A review of rare cutaneous adverse reactions associated with GLP-1 agonists catalogued skin reactions described in published case reports and case series, and reported that such events were uncommon relative to gastrointestinal effects (PMID 38795152).

Two further safety literatures concern semaglutide specifically rather than dulaglutide or exenatide. A systematic review and meta-analysis examined semaglutide and cancer outcomes and reported its pooled findings for that agent (PMID 37531876), and a 2025 ophthalmology study examined a possible association between semaglutide and nonarteritic anterior ischemic optic neuropathy (PMID 39976940). Neither addressed dulaglutide or exenatide, and neither supports extrapolation across the class.

Pregnancy

A review of GLP-1 receptor agonist use in pregnancy summarised the available human and animal data and reported that evidence in pregnant populations remains limited, with the literature drawn largely from inadvertent exposures and registry data rather than from randomized trials (PMID 39181497). Questions about pregnancy, breastfeeding or pregnancy planning belong with a prescribing clinician.

Regulatory status

Dulaglutide and exenatide are both approved prescription medicines for type 2 diabetes in the United States and in the European Union, dispensed under prescription and administered under medical supervision. Exenatide is marketed in short-acting and extended-release formulations, a distinction that affects how its trials were designed; the class review described duration of action as a defining feature across approved GLP-1 receptor agonists (PMID 33068776). Approved labelling, indications and monitoring requirements are set by regulators and by the prescribing clinician, not by summaries of the literature.

What the literature does not settle

• Direct randomized comparison between dulaglutide and exenatide is absent from the papers cited on this page, so no between-drug superiority or equivalence claim appears here.
• Pooled class estimates reported for cardiovascular and kidney endpoints describe the class average across trials with differing designs (PMID 31422062).
• Agent-specific safety findings reported for semaglutide, including the cancer meta-analysis (PMID 37531876), concern that molecule and were not reported for dulaglutide or exenatide.
• Long-term data in children, adolescents and pregnancy remain limited in the reviews that examined those populations (PMID 39065679, PMID 39181497).

Related reading

• Dulaglutide: what the literature reports
• Exenatide: what the literature reports

References

• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis (Annals of Internal Medicine, 2020)
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (The Lancet Diabetes & Endocrinology, 2019)
• Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients (Journal of the American College of Cardiology, 2025)
• Anti-diabetic drugs and weight loss in patients with type 2 diabetes (Pharmacological Research, 2021)
• Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis (Pharmaceuticals, 2024)
• Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature (Archives of Dermatological Research, 2024)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)
• Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation (Frontiers in Endocrinology, 2021)
• Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6 (Frontiers in Endocrinology, 2021)
• Semaglutide and cancer: A systematic review and meta-analysis (Diabetes & Metabolic Syndrome, 2023)
• Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (JAMA Ophthalmology, 2025)